Stem definition | Drug id | CAS RN |
---|---|---|
retinol derivatives | 78 | 55079-83-9 |
Dose | Unit | Route |
---|---|---|
35 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.83 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 59 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 28, 1996 | FDA | STIEFEL LABS INC |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Psoriasis | 729.35 | 19.87 | 311 | 6594 | 78293 | 46600864 |
Skin exfoliation | 93.24 | 19.87 | 59 | 6846 | 32879 | 46646278 |
Skin haemorrhage | 91.53 | 19.87 | 34 | 6871 | 5857 | 46673300 |
Psoriatic arthropathy | 90.29 | 19.87 | 60 | 6845 | 36319 | 46642838 |
Pruritus | 72.68 | 19.87 | 129 | 6776 | 242223 | 46436934 |
Drug ineffective | 68.54 | 19.87 | 237 | 6668 | 677601 | 46001556 |
Cutaneous T-cell lymphoma | 67.60 | 19.87 | 19 | 6886 | 1344 | 46677813 |
Pregnancy | 58.39 | 19.87 | 41 | 6864 | 27096 | 46652061 |
Dry skin | 57.48 | 19.87 | 48 | 6857 | 40968 | 46638189 |
Skin plaque | 56.71 | 19.87 | 24 | 6881 | 5811 | 46673346 |
Infected dermal cyst | 55.25 | 19.87 | 13 | 6892 | 451 | 46678706 |
Pustular psoriasis | 54.49 | 19.87 | 21 | 6884 | 3996 | 46675161 |
Rash pustular | 52.75 | 19.87 | 24 | 6881 | 6905 | 46672252 |
Erythema | 50.61 | 19.87 | 82 | 6823 | 142738 | 46536419 |
Rhesus antigen positive | 47.08 | 19.87 | 9 | 6896 | 111 | 46679046 |
Drug exposure before pregnancy | 46.77 | 19.87 | 12 | 6893 | 599 | 46678558 |
Wrong technique in device usage process | 44.55 | 19.87 | 15 | 6890 | 1938 | 46677219 |
Erythrodermic psoriasis | 42.31 | 19.87 | 12 | 6893 | 877 | 46678280 |
Skin fissures | 41.42 | 19.87 | 21 | 6884 | 7659 | 46671498 |
Squamous cell carcinoma | 38.15 | 19.87 | 20 | 6885 | 7816 | 46671341 |
Burning sensation | 37.12 | 19.87 | 39 | 6866 | 44372 | 46634785 |
Guttate psoriasis | 36.82 | 19.87 | 9 | 6896 | 368 | 46678789 |
Pregnancy of partner | 35.69 | 19.87 | 6 | 6899 | 33 | 46679124 |
Skin lesion | 34.82 | 19.87 | 30 | 6875 | 26683 | 46652474 |
Weaning failure | 32.97 | 19.87 | 8 | 6897 | 317 | 46678840 |
Blood immunoglobulin M decreased | 31.16 | 19.87 | 9 | 6896 | 702 | 46678455 |
Skin atrophy | 29.93 | 19.87 | 14 | 6891 | 4286 | 46674871 |
Immunoglobulins decreased | 29.61 | 19.87 | 9 | 6896 | 837 | 46678320 |
Type IIb hyperlipidaemia | 29.37 | 19.87 | 5 | 6900 | 30 | 46679127 |
Blood albumin increased | 29.20 | 19.87 | 9 | 6896 | 877 | 46678280 |
Lipids increased | 28.06 | 19.87 | 9 | 6896 | 999 | 46678158 |
Abortion induced | 28.06 | 19.87 | 18 | 6887 | 10242 | 46668915 |
Lip dry | 27.63 | 19.87 | 12 | 6893 | 3092 | 46676065 |
Ichthyosis | 27.30 | 19.87 | 5 | 6900 | 48 | 46679109 |
Onychalgia | 27.24 | 19.87 | 8 | 6897 | 661 | 46678496 |
Sunburn | 26.65 | 19.87 | 11 | 6894 | 2501 | 46676656 |
Exposure via body fluid | 25.01 | 19.87 | 7 | 6898 | 487 | 46678670 |
Tanning | 24.66 | 19.87 | 5 | 6900 | 85 | 46679072 |
Injection site bruising | 24.07 | 19.87 | 28 | 6877 | 35608 | 46643549 |
Increased bronchial secretion | 23.91 | 19.87 | 9 | 6896 | 1605 | 46677552 |
Inappropriate schedule of product administration | 23.89 | 19.87 | 38 | 6867 | 64975 | 46614182 |
Rickets | 23.79 | 19.87 | 4 | 6901 | 22 | 46679135 |
Blood immunoglobulin G decreased | 22.63 | 19.87 | 9 | 6896 | 1859 | 46677298 |
Death | 22.16 | 19.87 | 11 | 6894 | 335537 | 46343620 |
Mean cell haemoglobin increased | 22.06 | 19.87 | 9 | 6896 | 1987 | 46677170 |
Exposure during pregnancy | 21.91 | 19.87 | 49 | 6856 | 108163 | 46570994 |
Cellulitis | 21.71 | 19.87 | 38 | 6867 | 70250 | 46608907 |
Keratoacanthoma | 21.63 | 19.87 | 6 | 6899 | 404 | 46678753 |
Toxicity to various agents | 21.34 | 19.87 | 3 | 6902 | 211763 | 46467394 |
Psoriasis area severity index increased | 21.03 | 19.87 | 4 | 6901 | 48 | 46679109 |
Mastitis | 20.83 | 19.87 | 9 | 6896 | 2289 | 46676868 |
Maternal exposure before pregnancy | 20.57 | 19.87 | 11 | 6894 | 4470 | 46674687 |
Blister | 20.56 | 19.87 | 29 | 6876 | 44602 | 46634555 |
Toxic goitre | 20.16 | 19.87 | 3 | 6902 | 6 | 46679151 |
Serum ferritin decreased | 20.16 | 19.87 | 8 | 6897 | 1644 | 46677513 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Psoriasis | 724.72 | 19.96 | 278 | 5324 | 42228 | 29904648 |
Vein rupture | 199.20 | 19.96 | 41 | 5561 | 589 | 29946287 |
Drug ineffective | 143.63 | 19.96 | 239 | 5363 | 340148 | 29606728 |
Skin plaque | 131.72 | 19.96 | 42 | 5560 | 3620 | 29943256 |
Venous injury | 111.54 | 19.96 | 22 | 5580 | 251 | 29946625 |
Injection site haemorrhage | 100.44 | 19.96 | 42 | 5560 | 7813 | 29939063 |
Injection site papule | 85.14 | 19.96 | 18 | 5584 | 296 | 29946580 |
Erythrodermic psoriasis | 84.03 | 19.96 | 21 | 5581 | 741 | 29946135 |
Injection site swelling | 83.14 | 19.96 | 38 | 5564 | 8742 | 29938134 |
Cutaneous T-cell lymphoma | 72.36 | 19.96 | 21 | 5581 | 1314 | 29945562 |
Pityriasis rubra pilaris | 69.05 | 19.96 | 12 | 5590 | 63 | 29946813 |
Skin erosion | 58.49 | 19.96 | 19 | 5583 | 1734 | 29945142 |
Granuloma annulare | 57.93 | 19.96 | 11 | 5591 | 101 | 29946775 |
Squamous cell carcinoma | 57.27 | 19.96 | 31 | 5571 | 10219 | 29936657 |
Inappropriate schedule of product administration | 56.78 | 19.96 | 52 | 5550 | 39676 | 29907200 |
Dermatitis exfoliative generalised | 53.31 | 19.96 | 20 | 5582 | 2795 | 29944081 |
Squamous cell carcinoma of skin | 52.19 | 19.96 | 28 | 5574 | 9067 | 29937809 |
Pain in extremity | 49.41 | 19.96 | 80 | 5522 | 110141 | 29836735 |
Myalgia | 46.30 | 19.96 | 64 | 5538 | 76603 | 29870273 |
Pustular psoriasis | 39.86 | 19.96 | 14 | 5588 | 1621 | 29945255 |
Hypercholesterolaemia | 39.75 | 19.96 | 22 | 5580 | 7570 | 29939306 |
Hyperkeratosis | 39.73 | 19.96 | 17 | 5585 | 3340 | 29943536 |
Muscular weakness | 39.72 | 19.96 | 54 | 5548 | 63591 | 29883285 |
Skin exfoliation | 38.40 | 19.96 | 33 | 5569 | 23139 | 29923737 |
Dermatitis exfoliative | 37.38 | 19.96 | 21 | 5581 | 7435 | 29939441 |
Keratoacanthoma | 36.38 | 19.96 | 10 | 5592 | 513 | 29946363 |
Induration | 35.70 | 19.96 | 11 | 5591 | 845 | 29946031 |
Basal cell carcinoma | 35.34 | 19.96 | 27 | 5575 | 16041 | 29930835 |
Malignant melanoma stage I | 34.22 | 19.96 | 7 | 5595 | 97 | 29946779 |
Psoriatic arthropathy | 33.60 | 19.96 | 26 | 5576 | 15735 | 29931141 |
Neuroendocrine tumour of the lung metastatic | 33.52 | 19.96 | 7 | 5595 | 108 | 29946768 |
Insomnia | 32.95 | 19.96 | 61 | 5541 | 93275 | 29853601 |
Myasthenia gravis | 31.65 | 19.96 | 14 | 5588 | 2978 | 29943898 |
Therapeutic product effect incomplete | 31.27 | 19.96 | 35 | 5567 | 33799 | 29913077 |
Macule | 31.10 | 19.96 | 10 | 5592 | 883 | 29945993 |
Retinal disorder | 30.10 | 19.96 | 10 | 5592 | 979 | 29945897 |
Skin injury | 29.96 | 19.96 | 10 | 5592 | 993 | 29945883 |
Erythema | 29.07 | 19.96 | 52 | 5550 | 77399 | 29869477 |
Pruritus | 28.47 | 19.96 | 66 | 5536 | 118138 | 29828738 |
Decreased immune responsiveness | 27.59 | 19.96 | 10 | 5592 | 1268 | 29945608 |
Pain of skin | 25.73 | 19.96 | 13 | 5589 | 3720 | 29943156 |
Hepatic cirrhosis | 22.94 | 19.96 | 21 | 5581 | 15978 | 29930898 |
Sticky skin | 22.75 | 19.96 | 3 | 5599 | 0 | 29946876 |
Cutaneous symptom | 22.61 | 19.96 | 6 | 5596 | 269 | 29946607 |
Type 2 diabetes mellitus | 21.75 | 19.96 | 19 | 5583 | 13603 | 29933273 |
Death | 20.56 | 19.96 | 22 | 5580 | 357261 | 29589615 |
Hepatic fibrosis | 20.47 | 19.96 | 11 | 5591 | 3569 | 29943307 |
Drug intolerance | 20.40 | 19.96 | 33 | 5569 | 45258 | 29901618 |
Skin lesion | 20.36 | 19.96 | 21 | 5581 | 18473 | 29928403 |
Superficial spreading melanoma stage unspecified | 20.21 | 19.96 | 5 | 5597 | 169 | 29946707 |
Skin disorder | 20.18 | 19.96 | 17 | 5585 | 11591 | 29935285 |
Source | Code | Description |
---|---|---|
ATC | D05BB02 | DERMATOLOGICALS ANTIPSORIATICS ANTIPSORIATICS FOR SYSTEMIC USE Retinoids for treatment of psoriasis |
FDA CS | M0018962 | Retinoids |
FDA EPC | N0000175607 | Retinoid |
MeSH PA | D003879 | Dermatologic Agents |
MeSH PA | D007641 | Keratolytic Agents |
CHEBI has role | CHEBI:50176 | desquamating agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Severe Recalcitrant Psoriasis | indication | ||
Lichen planus | off-label use | 4776004 | DOID:9201 |
Keratosis follicularis | off-label use | 48611009 | DOID:2734 |
Lamellar ichthyosis | off-label use | 205550003 | |
Ichthyosiform erythroderma | off-label use | 268282005 | |
Primary cutaneous T-cell lymphoma | off-label use | 400122007 | |
Alcoholism | contraindication | 7200002 | |
Hypercholesterolemia | contraindication | 13644009 | |
Depressive disorder | contraindication | 35489007 | |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Night blindness | contraindication | 65194006 | DOID:8499 |
Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Premature epiphyseal closure | contraindication | 89493005 | |
Liver function tests abnormal | contraindication | 166603001 | |
Hypoalphalipoproteinemia | contraindication | 190785000 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Hypertrophy of bone | contraindication | 203514008 | DOID:205 |
Drug-induced hepatitis | contraindication | 235876009 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Cardiovascular event risk | contraindication | 395112001 | |
Visual impairment | contraindication | 397540003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Psychiatric Disturbance | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.17 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Retinoic acid receptor alpha | Nuclear hormone receptor | AGONIST | WOMBAT-PK | CHEMBL | |||||
Retinoic acid receptor gamma | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL | |||||
Bile salt export pump | Transporter | IC50 | 4.74 | CHEMBL | |||||
Bile salt export pump | Unclassified | IC50 | 4.71 | CHEMBL |
ID | Source |
---|---|
LCH760E9T7 | UNII |
4021061 | VUID |
N0000148524 | NUI |
D02754 | KEGG_DRUG |
69427-46-9 | SECONDARY_CAS_RN |
C0050559 | UMLSCUI |
CHEBI:50173 | CHEBI |
CHEMBL1131 | ChEMBL_ID |
5284513 | PUBCHEM_CID |
DB00459 | DRUGBANK_ID |
D017255 | MESH_DESCRIPTOR_UI |
5530 | INN_ID |
7598 | IUPHAR_LIGAND_ID |
16818 | RXNORM |
11379 | MMSL |
117161 | MMSL |
4128 | MMSL |
d03836 | MMSL |
004121 | NDDF |
108914001 | SNOMEDCT_US |
386938006 | SNOMEDCT_US |
4021061 | VANDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1135 | CAPSULE | 10 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1136 | CAPSULE | 25 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-1138 | CAPSULE | 17.50 mg | ORAL | ANDA | 24 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1667 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1668 | CAPSULE | 17.50 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1669 | CAPSULE | 25 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1698 | CAPSULE | 22.50 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1750 | CAPSULE | 10 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1751 | CAPSULE | 17.50 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1752 | CAPSULE | 22.50 mg | ORAL | ANDA | 17 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1753 | CAPSULE | 25 mg | ORAL | ANDA | 17 sections |
SORIATANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0145-0090 | CAPSULE | 10 mg | ORAL | NDA | 27 sections |
SORIATANE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0145-0091 | CAPSULE | 25 mg | ORAL | NDA | 27 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7020 | CAPSULE | 10 mg | ORAL | ANDA | 28 sections |
Acitretin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-7023 | CAPSULE | 25 mg | ORAL | ANDA | 28 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-086 | CAPSULE | 10 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-087 | CAPSULE | 17.50 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-088 | CAPSULE | 25 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-080 | CAPSULE | 10 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-081 | CAPSULE | 17.50 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42794-083 | CAPSULE | 25 mg | ORAL | ANDA | 25 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-894 | CAPSULE | 10 mg | ORAL | NDA authorized generic | 16 sections |
ACITRETIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66993-896 | CAPSULE | 25 mg | ORAL | NDA authorized generic | 16 sections |